Epigenetic Strategies to Boost Cancer Immunotherapies
Open Access
- 23 May 2017
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (6) , 1108
Abstract
Recently, immunotherapeutic approaches have shown impressive responses in a subset of cancer patients. However, the rate of success is low and a large percentage of treated patients do not experience clinical benefits. Therefore, additional strategies are needed to improve responses and select responsive patients. Emerging data suggest that epigenetic drugs can improve the responses to immunotherapy. Understanding the mechanisms of resistance to immunotherapy and the epigenetic events that take place during immune evasion is critical to providing a rational combined use of immunotherapies and epigenetic drugs. This review focuses in the epigenetic mechanisms involved in the responses to immunotherapy and how current drugs that target epigenetic regulators impact on them.Keywords
This publication has 58 references indexed in Scilit:
- Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited successBioEssays, 2016
- Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia TherapyCancer Research, 2015
- The interplay of histone modifications – writers that readEMBO Reports, 2015
- Targeting bromodomains: epigenetic readers of lysine acetylationNature Reviews Drug Discovery, 2014
- DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer.2013
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-EnhancersCell, 2013
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemiaNature, 2011
- Selective inhibition of BET bromodomainsNature, 2010
- Nucleosomal Fluctuations Govern the Transcription Dynamics of RNA Polymerase IIScience, 2009
- Structure and ligand of a histone acetyltransferase bromodomainNature, 1999